Cost-effectiveness of population-based screening for chronic obstructive pulmonary disease in China: a simulation modeling study

• Published in: The Lancet regional health. Western Pacific 2024-05, Vol.46, p.101065-101065, Article 101065
• Main Authors: Chen, Qiushi, Fan, Yiwen, Huang, Ke, Li, Wei, Geldsetzer, Pascal, Bärnighausen, Till, Yang, Ting, Wang, Chen, Chen, Simiao
• Format: Article
• Language: English
• Subjects: Chronic obstructive pulmonary disease; Cost-effectiveness analysis; Microsimulation; Population-based screening; Public health policy
• ISSN: 2666-6065; 2666-6065
• DOI: 10.1016/j.lanwpc.2024.101065

China has the highest disease burden of chronic obstructive pulmonary disease (COPD) in the world; however, the diagnosis rate remains low. Screening for COPD in the population may improve early diagnosis and long-term health outcomes for patients with COPD. In this study, we aimed to evaluate the cost-effectiveness of population-based COPD screening policies in China. We developed a microsimulation model that simulated incidence, natural history, and clinical management of COPD over a lifetime horizon among the general population aged 35–80 years in China. We evaluated population-based screening policies with different screening methods (one-step with COPD Screening Questionnaire or two-step with additional portable spirometer test) and frequencies (one-time or every 1–10 years). We calculated the incremental cost-effectiveness ratio (ICER) of the screening policies compared with the status quo (without screening) and identified the most cost-effective screening policy. Scenario and sensitivity analyses were performed to assess the impact of key parameters and the robustness of model results. Compared with the status quo, all population-based COPD screening policies were cost-effective with estimated ICERs ranging between $8034 and $13,209 per quality-adjusted-life-year (QALY), all under the willingness-to-pay value of $38,441/QALY (three times China's gross domestic product per capita). A total of 0.39%–8.10% of COPD-related deaths and 0.58%–2.70% of COPD exacerbations were projected to be averted by COPD screening. Among all screening policies, annual two-step screening was the most cost-effective. Improving the linkage from screening to diagnosis and treatment could further increase population health benefits and the cost-effectiveness of COPD screening. Population-based screening for COPD could be cost-effective in China. Offering public programs for COPD screening similar to existing preventive health services for other chronic diseases could be a promising strategy to improve population health outcomes and mitigate the disease burden of COPD in China. Alexander von Humboldt Foundation, National Natural Science Foundation of China, CAMS Innovation Fund for Medical Science, Chinese Academy of Engineering project, and Horizon Europe.